Meta-analysis of gemcitabine at 30 min standard-dose infusion versus prolonged low-dose infusion for advanced non-small cell lung cancer

doi:10.5246/jcps.2017.10.086

Abstract

Abstract:

To evaluate the efficacy and safety of gemcitabine (GEM) at 30 min standard-dose infusion (30 min-SDI) compared with prolonged low-dose infusion(P-LDI) in patients withadvanced non-small-cell lung cancer (NSCLC). Electronic databases including Pubmed, EMbase, Cochrane Library, CNKI, CBM, and VIP were searched using keywords “GEM”,“P-LDI”, and “NSCLC”. Review Manager 5.3 was used to perform the meta-analysis. Primary endpoints were overall response rate (ORR) and 1-year survival rate (1-year SR). Secondary endpoints were grade 3/4 hematotoxicity and nausea/vomiting. Six randomized controlled trials (RCTs) with a total of 637 patients were included.The results showed that P-LDIwas superior in ORR (OR = 1.50, 95% CI: 1.08–2.10, P = 0.02), but had an equal 1-year SR (OR = 1.27, 95 % CI: 0.90–1.79, P = 0.18) as compared with 30 min-SDI.For grade 3/4 adverse events, there was no significant difference in anemia (OR = 1.84, 95% CI: 0.61–5.57, P = 0.28) and nausea/vomiting (OR = 1.15, 95% CI: 0.63–2.12, P = 0.64) between thetwo treatments. However, patients with P-LDI experiencedless leukopenia (OR = 0.64, 95% CI: 0.43–0.97, P = 0.04)and thrombocytopenia (OR = 0.37, 95% CI: 0.17–0.80, P = 0.01). P-LDI was superior in terms of ORR, experienced less grade 3/4thrombocytopenia and leukopenia compared with 30 min-SDI, and could be a viable treatment option for advanced NSCLC.

Key words: Gemcitabine, Prolonged low-dose infusion, Non-small-cell lung cancer, Meta-analysis, Randomized controlled trials

CLC Number:

R954

Supporting:

Dehua Zhao, Mingming Chu, Jing Chen, Jisheng Wang. Meta-analysis of gemcitabine at 30 min standard-dose infusion versus prolonged low-dose infusion for advanced non-small cell lung cancer[J]. Journal of Chinese Pharmaceutical Sciences, 2017, 26(10): 763-770.

References

[1] Ferlay, J.; Steliarova, F.E.; Lortet, T.J.; Rosso, S.; Coebergh, J.W.; Comber, H.; Forman, D.; Bray, F. Eur. J. Cancer. 2013, 49, 1374-1403.

[2] Ettinger, D.S.; Wood, D.E.; Aisner, D.L.; Akerley, W.; Bauman, J.; Chirieac, L.R.; D'Amico, T.A.; DeCamp, M.M.; Dilling, T.J.; Dobelbower, M.; Doebele, R.C.; Govindan, R.; Gubens, M.A.; Hennon, M.; Horn, L.; Komaki, R.; Lackner, R.P.; Lanuti, M.; Leal, T.A.; Leisch, L.J.; Lilenbaum, R.; Lin, J.; Yang, S.C.; Gregory, K.; Hughes, M. J. Natl. Compr. Canc. Netw. 2017, 15, 504-535.

[3] Gridelli, C.; Kaukel, E.; Gregorc, V.; Migliorino, M.R.; Müller, T.R.; Manegold, C.; Favaretto, A.; Martoni, A.; Caffo, O.; Schmittel, A.; Rossi, A.; Russo, F.; Peterson, P.; Muñoz, M.; Reck, M. J. Thorac. Oncol. 2007, 2, 221-229.

[4] D’Addario, G.; Felip, E.; ESMO Guidelines Working Group. Ann. Oncol. 2008, 19, 39-40.

[5] Cattel, L.; Airoldi, M.; Delprino, L.; Passera, R.; Milla, P.; Pedani, F. Ann. Oncol. 2006, 17, 142-147.

[6] Qiu, M.T.; Ding, X.X.; Hu, J.W.; Tian, H.Y.; Yin, R.; Xu, L. Cancer Chemother. Pharmacol. 2012, 70, 861-873.

[7] Vrankar, M.; Zwitter, M.; Bavcar, T.; Milic, A.; Kovac, V. Radiol Oncol. 2014, 48, 369-380.

[8] Zwitter, M.; Kovac, V.; Smrdel, U.; Vrankar, M.; Zadnik, V. Thorac Oncol. 2009, 4, 1148-1155.

[9] Zwitter, M.; Kovac, V.; Rajer, M.; Vrankar, M.; Smrdel, U. Anticancer Drugs. 2010, 21, 662-668.

[10] Zwitter, M.; Kovac, V.; Smrdel, U.; Kocijancic, I.; Segedin, B.; Vrankar, M. Anticancer Drugs. 2005, 16, 1129-1134.

[11] Beniwal, S.K.; Patel, K.M.; Shukla, S.; Parikh, B.J.; Shah, S.; Patel, A. Indian J. Cancer. 2012, 49, 202-208.

[12] Xiong, J.P.; Xu, J.; Zhong, L.X.; Zhang, L.; Qiu, F.; Luo, H.; Lian, H.Y.; Guo, Y.L. Chin. Clin. Oncol. 2005, 10, 643-646.

[13] Shang, Z.T.; Chen, S.W. Chin J. Cancer Prev. Treat. 2010, 17, 1568-1570.

[14] Guan, H.H.; Yang, H.K.; Zhou, L.; Xu, J.F.; Chen, Y. Anti-Tumor Pharm. 2014, 4, 277-281.

[15] Xiong, J.P.; Zhang, L.; Zhong, L.X.; Qiu, F.; Guo, Y.L.; Lian, H.Y.; Luo, H. Chin. J. Cancer. 2006, 25, 995-998.

[16] Yang, H.K. Eval. Anal. Drug Use Hosp. China. 2008, 8, 380-381.

[17] Wu, Z.Y.; Guan, H.H.; Lin, Z.X.; Yang, H.K.; Zhou, L.; Cai, Q.C. J. Chemotherapy. 2014, 26, 306-311.

[18] Anderson, H.; Thatcher, N.; Walling, J.; Hansen, H. British J. Cancer. 1996, 74, 460-462.

[19] Chen, J.; Tao, Q.S.; Pang, L.R.; Li, H.; Xu, C.H.; Huang, J.; Zeng, H.Y.; Yang, C. Zhejiang Med. J. 2013, 35, 1823-1826.

[20] Plunkett, W.; Huang, P.; Xu, Y.Z,; Heinemann, V.; Grunewald, R.; Gandhi, V. Semin. Oncol. 1995, 22, 3-10.

[21] Grunewald, R.; Kantarjian, H.; Du, M.; Faucher, K.; Tarassoff, P.; Plunkett, W. J. Clin. Oncol. 1992, 10, 406-413.

[22] Hui, Y.; Ma, W.W.; Xiong, K.; Zeng, H.H. J. Chin. Pharma. Sci. 2013, 22, 177-183.

[23] Patel, S.R.; Gandhi, V.; Jenkins, J.; Jenkins, J.; Papadopolous, N.; Burgess, M.A.; Plager, C.; Plunkett, W.; Benjamin, R.S. J. Clin. Oncol. 2001, 19, 3483-3489.
[24] Soo, R.A.; Wang, L.Z.; Tham, L.S.;, Yong, W.P.; Boyer, M.; Lim, H.L.; Lee, H.S.; Millward, M.; Liang, S.; Beagle, P.; Lee, S.C. Goh, B.C. Ann Oncol. 2006, 17, 1128-1133.